| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease.
|
Mov Disord
|
2013
|
1.94
|
|
2
|
Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor.
|
Mov Disord
|
2013
|
1.68
|
|
3
|
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.
|
Mov Disord
|
2008
|
1.56
|
|
4
|
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.
|
Lancet Neurol
|
2013
|
1.56
|
|
5
|
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
|
Mov Disord
|
2005
|
1.54
|
|
6
|
Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study.
|
Arch Neurol
|
2010
|
1.38
|
|
7
|
Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment.
|
Am J Manag Care
|
2008
|
1.33
|
|
8
|
Basal ganglia hypoactivity during grip force in drug naïve Parkinson's disease.
|
Hum Brain Mapp
|
2010
|
1.21
|
|
9
|
Force control and disease severity in Parkinson's disease.
|
Mov Disord
|
2005
|
1.08
|
|
10
|
Treatment of focal dystonias with botulinum neurotoxin.
|
Toxicon
|
2008
|
1.06
|
|
11
|
Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.
|
Arch Neurol
|
2009
|
1.05
|
|
12
|
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.
|
J Int Neuropsychol Soc
|
2010
|
1.04
|
|
13
|
Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease.
|
J Clin Exp Neuropsychol
|
2010
|
1.03
|
|
14
|
Effect of medication on EMG patterns in individuals with Parkinson's disease.
|
Mov Disord
|
2002
|
1.01
|
|
15
|
Daytime sleepiness, agonist therapy, and driving in Parkinson disease.
|
JAMA
|
2002
|
0.97
|
|
16
|
Differences in brain activation between tremor- and nontremor-dominant Parkinson disease.
|
JAMA Neurol
|
2013
|
0.95
|
|
17
|
Greater impairment of extension movements as compared to flexion movements in Parkinson's disease.
|
Exp Brain Res
|
2004
|
0.95
|
|
18
|
Parkinson's disease--Part 3: Neuropsychiatric symptoms.
|
Am J Manag Care
|
2008
|
0.92
|
|
19
|
Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy.
|
PLoS One
|
2013
|
0.89
|
|
20
|
Distinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy.
|
Hum Brain Mapp
|
2014
|
0.89
|
|
21
|
A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.
|
J Neural Transm (Vienna)
|
2013
|
0.88
|
|
22
|
Benefits and risks of pharmacological treatments for essential tremor.
|
Drug Saf
|
2003
|
0.88
|
|
23
|
Restless legs syndrome in Parkinson's disease and other neurodegenerative diseases of the central nervous system.
|
Mov Disord
|
2007
|
0.87
|
|
24
|
Strength deficits in primary focal hand dystonia.
|
Mov Disord
|
2006
|
0.87
|
|
25
|
Variability of EMG patterns: a potential neurophysiological marker of Parkinson's disease?
|
Clin Neurophysiol
|
2008
|
0.85
|
|
26
|
Parkinson's disease--Part 2: Treatment of motor symptoms.
|
Am J Manag Care
|
2008
|
0.85
|
|
27
|
Rating scale for psychogenic movement disorders: scale development and clinimetric testing.
|
Mov Disord
|
2005
|
0.85
|
|
28
|
Rate of force production and relaxation is impaired in patients with focal hand dystonia.
|
Parkinsonism Relat Disord
|
2006
|
0.85
|
|
29
|
Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study.
|
Mov Disord
|
2010
|
0.84
|
|
30
|
Stimulation-induced parkinsonism after posteroventral deep brain stimulation of the globus pallidus internus for craniocervical dystonia.
|
J Neurosurg
|
2009
|
0.84
|
|
31
|
Tai chi for patients with Parkinson's disease.
|
N Engl J Med
|
2012
|
0.82
|
|
32
|
Designing clinical trials for dystonia.
|
Neurotherapeutics
|
2014
|
0.82
|
|
33
|
Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo.
|
Mov Disord
|
2010
|
0.82
|
|
34
|
Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia.
|
Tremor Other Hyperkinet Mov (N Y)
|
2013
|
0.80
|
|
35
|
Early-onset primary dystonia.
|
Handb Clin Neurol
|
2011
|
0.80
|
|
36
|
Changes in the relationship between movement velocity and movement distance in primary focal hand dystonia.
|
J Mot Behav
|
2008
|
0.80
|
|
37
|
Treatment of dystonia.
|
Clin Neuropharmacol
|
2003
|
0.77
|
|
38
|
Jaw-opening dystonia: Quality of life after botulinum toxin injections.
|
Ear Nose Throat J
|
2011
|
0.77
|
|
39
|
Effects of Endurance Exercise Training on The Motor and Non-Motor Features of Parkinson's Disease: A Review.
|
J Parkinsons Dis
|
2015
|
0.77
|
|
40
|
Association of daytime napping and Parkinsonian signs in Alzheimer's disease.
|
Sleep Med
|
2006
|
0.76
|
|
41
|
Sleep disorders in Parkinson's disease.
|
Handb Clin Neurol
|
2011
|
0.75
|
|
42
|
Effects of 2 Years of Exercise on Gait Impairment in People With Parkinson Disease: The PRET-PD Randomized Trial.
|
J Neurol Phys Ther
|
2017
|
0.75
|
|
43
|
Restless legs syndrome.
|
Prim Care
|
2005
|
0.75
|
|
44
|
Effects of Endurance Exercise Training on The Motor and Non-Motor Features of Parkinson's Disease: A Review.
|
J Parkinsons Dis
|
2015
|
0.75
|